Non-cognate  ||| S:0 E:12 ||| JJ
bystander  ||| S:12 E:22 ||| JJ
cytolysis  ||| S:22 E:32 ||| NN
by  ||| S:32 E:35 ||| IN
clonal  ||| S:35 E:42 ||| JJ
epitope-specific  ||| S:42 E:59 ||| JJ
CTL  ||| S:59 E:63 ||| NN
lines  ||| S:63 E:69 ||| NNS
through  ||| S:69 E:77 ||| IN
CD28-CD80  ||| S:77 E:87 ||| CD
interaction  ||| S:87 E:99 ||| CD
inhibits  ||| S:99 E:108 ||| JJ
antibody  ||| S:108 E:117 ||| NN
production ||| S:117 E:127 ||| NN
:  ||| S:127 E:129 ||| :
A  ||| S:129 E:131 ||| DT
potential  ||| S:131 E:141 ||| JJ
caveat  ||| S:141 E:148 ||| NN
to  ||| S:148 E:151 ||| TO
CD8  ||| S:151 E:155 ||| CD
T-cell  ||| S:155 E:162 ||| JJ
immunotherapy  ||| S:162 E:176 ||| JJ
Adoptive  ||| S:176 E:185 ||| JJ
transfer  ||| S:185 E:194 ||| NN
of  ||| S:194 E:197 ||| IN
virus  ||| S:197 E:203 ||| NN
epitope-specific  ||| S:203 E:220 ||| JJ
CD8  ||| S:220 E:224 ||| CD
T  ||| S:224 E:226 ||| NN
cells  ||| S:226 E:232 ||| NNS
is  ||| S:232 E:235 ||| VBZ
an  ||| S:235 E:238 ||| DT
immunotherapy  ||| S:238 E:252 ||| JJ
option  ||| S:252 E:259 ||| NN
to  ||| S:259 E:262 ||| TO
control  ||| S:262 E:270 ||| VB
cytomegalovirus  ||| S:270 E:286 ||| NNS
( ||| S:286 E:287 ||| -LRB-
CMV ||| S:287 E:290 ||| NNP
)  ||| S:290 E:292 ||| -RRB-
infection  ||| S:292 E:302 ||| NN
and  ||| S:302 E:306 ||| CC
prevent  ||| S:306 E:314 ||| VB
CMV  ||| S:314 E:318 ||| JJ
organ  ||| S:318 E:324 ||| NN
disease  ||| S:324 E:332 ||| NN
in  ||| S:332 E:335 ||| IN
immunocompromised  ||| S:335 E:353 ||| JJ
solid  ||| S:353 E:359 ||| JJ
organ  ||| S:359 E:365 ||| NN
transplantation  ||| S:365 E:381 ||| NN
( ||| S:381 E:382 ||| -LRB-
SOT ||| S:382 E:385 ||| NNP
)  ||| S:385 E:387 ||| -RRB-
and  ||| S:387 E:391 ||| CC
hematopoietic  ||| S:391 E:405 ||| JJ
cell  ||| S:405 E:410 ||| NN
transplantation  ||| S:410 E:426 ||| NN
( ||| S:426 E:427 ||| -LRB-
HCT ||| S:427 E:430 ||| NNP
)  ||| S:430 E:432 ||| -RRB-
recipients ||| S:432 E:442 ||| NNS
.  ||| S:442 E:444 ||| .
The  ||| S:444 E:448 ||| DT
therapy  ||| S:448 E:456 ||| NN
aims  ||| S:456 E:461 ||| VBZ
at  ||| S:461 E:464 ||| IN
an  ||| S:464 E:467 ||| DT
early ||| S:467 E:472 ||| JJ
,  ||| S:472 E:474 ||| ,
selective  ||| S:474 E:484 ||| JJ
recognition  ||| S:484 E:496 ||| NN
and  ||| S:496 E:500 ||| CC
cytolysis  ||| S:500 E:510 ||| NN
of  ||| S:510 E:513 ||| IN
infected  ||| S:513 E:522 ||| JJ
cells  ||| S:522 E:528 ||| NNS
for  ||| S:528 E:532 ||| IN
preventing  ||| S:532 E:543 ||| VBG
viral  ||| S:543 E:549 ||| JJ
spread  ||| S:549 E:556 ||| NN
in  ||| S:556 E:559 ||| IN
tissues  ||| S:559 E:567 ||| NNS
with  ||| S:567 E:572 ||| IN
no  ||| S:572 E:575 ||| DT
adverse  ||| S:575 E:583 ||| JJ
immunopathogenic  ||| S:583 E:600 ||| JJ
side-effects  ||| S:600 E:613 ||| NN
by  ||| S:613 E:616 ||| IN
attack  ||| S:616 E:623 ||| NN
of  ||| S:623 E:626 ||| IN
uninfected  ||| S:626 E:637 ||| JJ
bystander  ||| S:637 E:647 ||| JJ
cells ||| S:647 E:652 ||| NNS
.  ||| S:652 E:654 ||| .
Here  ||| S:654 E:659 ||| RB
we  ||| S:659 E:662 ||| PRP
describe  ||| S:662 E:671 ||| VBP
that  ||| S:671 E:676 ||| DT
virus  ||| S:676 E:682 ||| NN
epitope-specific ||| S:682 E:698 ||| NN
,  ||| S:698 E:700 ||| ,
cloned  ||| S:700 E:707 ||| VBN
T-cell  ||| S:707 E:714 ||| JJ
lines  ||| S:714 E:720 ||| NNS
lyse  ||| S:720 E:725 ||| JJ
target  ||| S:725 E:732 ||| NN
cells  ||| S:732 E:738 ||| NNS
that  ||| S:738 E:743 ||| WDT
present  ||| S:743 E:751 ||| VBP
the  ||| S:751 E:755 ||| DT
cognate  ||| S:755 E:763 ||| JJ
antigenic  ||| S:763 E:773 ||| JJ
peptide  ||| S:773 E:781 ||| NN
to  ||| S:781 E:784 ||| TO
the  ||| S:784 E:788 ||| DT
TCR ||| S:788 E:791 ||| NNP
,  ||| S:791 E:793 ||| ,
but  ||| S:793 E:797 ||| CC
simultaneously  ||| S:797 E:812 ||| RB
have  ||| S:812 E:817 ||| VB
the  ||| S:817 E:821 ||| DT
potential  ||| S:821 E:831 ||| JJ
to  ||| S:831 E:834 ||| TO
lyse  ||| S:834 E:839 ||| VB
uninfected  ||| S:839 E:850 ||| JJ
cells  ||| S:850 E:856 ||| NNS
expressing  ||| S:856 E:867 ||| VBG
the  ||| S:867 E:871 ||| DT
CD28  ||| S:871 E:876 ||| FW
ligand  ||| S:876 E:883 ||| FW
CD80  ||| S:883 E:888 ||| FW
( ||| S:888 E:889 ||| -LRB-
B7-1 ||| S:889 E:893 ||| NNP
) ||| S:893 E:894 ||| -RRB-
.  ||| S:894 E:896 ||| .
While  ||| S:896 E:902 ||| IN
TCR-mediated  ||| S:902 E:915 ||| JJ
cytolysis  ||| S:915 E:925 ||| NN
requires  ||| S:925 E:934 ||| VBZ
co-receptor  ||| S:934 E:946 ||| JJ
CD8  ||| S:946 E:950 ||| NN
and  ||| S:950 E:954 ||| CC
depends  ||| S:954 E:962 ||| VBZ
on  ||| S:962 E:965 ||| IN
perforin ||| S:965 E:973 ||| NN
,  ||| S:973 E:975 ||| ,
the  ||| S:975 E:979 ||| DT
TCR-independent  ||| S:979 E:995 ||| JJ
and  ||| S:995 E:999 ||| CC
viral  ||| S:999 E:1005 ||| JJ
epitope-independent  ||| S:1005 E:1025 ||| JJ
cytolysis  ||| S:1025 E:1035 ||| NN
through  ||| S:1035 E:1043 ||| IN
CD28-CD80  ||| S:1043 E:1053 ||| CD
signaling  ||| S:1053 E:1063 ||| NN
does  ||| S:1063 E:1068 ||| VBZ
not  ||| S:1068 E:1072 ||| RB
require  ||| S:1072 E:1080 ||| VB
CD8  ||| S:1080 E:1084 ||| CD
on  ||| S:1084 E:1087 ||| IN
the  ||| S:1087 E:1091 ||| DT
effector  ||| S:1091 E:1100 ||| JJ
cells  ||| S:1100 E:1106 ||| NNS
and  ||| S:1106 E:1110 ||| CC
is  ||| S:1110 E:1113 ||| VBZ
perforin-independent ||| S:1113 E:1133 ||| JJ
.  ||| S:1133 E:1135 ||| .
Importantly ||| S:1135 E:1146 ||| RB
,  ||| S:1146 E:1148 ||| ,
this  ||| S:1148 E:1153 ||| DT
non-cognate  ||| S:1153 E:1165 ||| JJ
cytolysis  ||| S:1165 E:1175 ||| JJ
pathway  ||| S:1175 E:1183 ||| NN
leads  ||| S:1183 E:1189 ||| VBZ
to  ||| S:1189 E:1192 ||| TO
bystander  ||| S:1192 E:1202 ||| VB
cytolysis  ||| S:1202 E:1212 ||| VBN
of  ||| S:1212 E:1215 ||| IN
CD80-expressing  ||| S:1215 E:1231 ||| CD
B-cell  ||| S:1231 E:1238 ||| JJ
blasts  ||| S:1238 E:1245 ||| NNS
and  ||| S:1245 E:1249 ||| CC
thereby  ||| S:1249 E:1257 ||| RB
inhibits  ||| S:1257 E:1266 ||| JJ
pan-specific  ||| S:1266 E:1279 ||| JJ
antibody  ||| S:1279 E:1288 ||| NN
production ||| S:1288 E:1298 ||| NN
.  ||| S:1298 E:1300 ||| .
